Management of guttate and generalized psoriasis vulgaris: Prospective randomized study

Croatian Medical Journal

Volumn 43, Issue 6, 2002, Pages 707-712

  Caca Biljanovska, Nina G ^a   V'Ickova Laskoska, Marija T ^a  

^a SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

Author keywords

Betamethasone; Psoriasis; PUVA therapy; Retinoids; Ultraviolet therapy

Indexed keywords

BETAMETHASONE DIPROPIONATE; PENICILLIN G; PSORALEN; RETINOID; ANTIINFLAMMATORY AGENT; BETAMETHASONE; PENICILLIN DERIVATIVE;

ACTINIC KERATOSIS; ARTICLE; BURN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; LENTIGO; MAJOR CLINICAL STUDY; NAUSEA; PHOTOAGING; PRURITUS; PSORIASIS VULGARIS; PUVA; RANDOMIZED CONTROLLED TRIAL; SKIN CARCINOMA; STATISTICAL ANALYSIS; STUDENT T TEST; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ADOLESCENT; ADULT; COMPARATIVE STUDY; FEMALE; MACEDONIA (REPUBLIC); MALE; MULTIMODALITY CANCER THERAPY; PHOTOTHERAPY; PROSPECTIVE STUDY; PSORIASIS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MACEDONIA (REPUBLIC); MALE; PENICILLINS; PROSPECTIVE STUDIES; PSORIASIS; PUVA THERAPY; RETINOIDS; TREATMENT OUTCOME; ULTRAVIOLET THERAPY;

EID: 0036884653     PISSN: 03539504     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Barker JN. Psoriasis as a T cell-mediated autoimmune disease. Hosp Med 1998;59:530-3.
2. Van Scott EJ, Ekel TM. Kinetics of hyperplasia in psoriasis. Arch Dermatol 1963;88:373-80.
3. Roenigk HH, Maibach HI, editors. Psoriasis. 3rd ed. New York (NY): Marcel Dekker; 1998.
4. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7.
5. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998;101:783-94.
6. Seifert M, Sterry W, Effenberger E, Rexin A, Friedrich M, Haeussler-Quade A, et al. The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human keratinocytes. Arch Dermatol Res 2000;292:164-72.
7. Harder J, Bartels J, Christophers E, Schroder JM. A peptide antibiotic from human skin. Nature 1997;387:861.
8. Henderson CA, Highet AS. Acute psoriasis associated with Lancefield group C and group G cutaneous streptococcal infections. Br J Dermatol 1988;118:559-61.
9. Valdimarsson H, Sigmundsdottir H, Jonsdottir I. Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin? Clin Exp Immunol 1997;107 Suppl 1:21-4.
10. Bohach GA, Fast DJ, Nelson RD, Schlievert PM. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 1990;17:251-72.
11. Chang JC, Smith LR, Froning KJ, Schwabe BJ, Laxer JA, Caralli LL, et al. CD8+ T cells in psoriatic lesions preferentially use T-cell receptor Vbeta 3 and/or Vbeta 13.1 genes. Ann N Y Acad Sci 1995;756:370-81.
12. Prinz JC. Which T cells cause psoriasis? Clin Exp Dermatol 1999;24:291-5.
13. Kotzin BL, Leung DY, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol 1993;54:99-166.
14. Scherer MT, Ignatowicz L, Winslow GM, Kappler JW, Marrack P. Superantigens: bacterial and viral proteins that manipulate the immune system. Annu Rev Cell Biol 1993;9:101-28.
15. Leung DY, Travers JB, Giorno R, Norris DA, Skinner R, Aelion J, et al. Evidence for streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest 1995;96:2106-12.
16. Torres BA, Johnson HM. Modulation of disease by superantigens. Curr Opin Immunol 1998;10:465-70.
17. Leung DY, Hauk P, Strickland I, Travers JB, Norris DA. The role of superantigens in human diseases: therapeutic implications for the treatment of skin diseases. Br J Dermatol 1998;139 Suppl 53:17-29.
18. Yarwood JM, Leung DY, Schlievert PM. Evidence for the involvement of bacterial superantigens in psoriasis, atopic dermatitis, and Kawasaki syndrome. FEMS Microbiol Lett 2000;192:1-7.
19. Krueger JG, Wolfe JT, Nabeya RT, Vallat VP, Gilleaudeau P, Heftler NS, et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995;182:2057-68.
20. Vallat VP, Gilleaudeau P, Battat L, Wolfe J, Nabeya R, Heftler N, et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994;180:283-96.
21. Ozawa M, Ferenczi K, Kikuchi T, Cardinale I, Austin LM, Coven TR, et al. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med 1999;189:711-8.
22. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001;45:649-61.
23. Saurat JH. Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol 1999;41(3 Pt 2):S2-6.
24. Gottlieb AB, Grossman RM, Khandke L, Carter DM, Sehgal PB, Fu SM, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol 1992;98:302-9.
25. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
26. Fredriksson T, Lassus A, Salde L. Reproducibility of clinical trials of topical glucocorticosteroids. Int J Dermatol 1983;22:536-9.
27. Weinstein GD, Gottlieb AB, editors. Therapy of moderate-to-severe psoriasis. Portland: National Psoriasis Foundation; 1993.
28. Rosenberg EW, Belew PW, Skinner RB. Treatment of psoriasis with antimicrobial agents. Semin Dermatol 1985;4:307-11.
29. Moseley H, Ferguson J. Photochemotherapy: a reappraisal of its use in dermatology. Drugs 1989;38:822-37.
30. Sakuntabhai A, Sharpe GR, Farr PM. Response of psoriasis to twice weekly PUVA. Br J Dermatol 1993;128:166-71.
31. Ortonne JP. From actinic keratosis to squamous cell carcinoma. Br J Dermatol 2002;146 Suppl 61:20-3.
32. Orfanos CE, Garbe C. Therapy of dermatologic diseases [in German]. Berlin, Heidelberg, New York: Springer Verlag; 1995.
33. Orfanos CE. Current treatment of psoriasis. Les Nouvelles Dermatologiques 1998;17 Suppl 1:32-43.
34. Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs 1997;53:358-88.
35. Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders. Drugs 1984;28:6-37.